CDXS vs. SMTI, IMMP, AKBA, EDAP, SENS, JYNT, VMD, DSGN, GLUE, and AXGN Should you be buying Codexis stock or one of its competitors? The main competitors of Codexis include Sanara MedTech (SMTI), Immutep (IMMP), Akebia Therapeutics (AKBA), Edap Tms (EDAP), Senseonics (SENS), Joint (JYNT), Viemed Healthcare (VMD), Design Therapeutics (DSGN), Monte Rosa Therapeutics (GLUE), and AxoGen (AXGN). These companies are all part of the "medical" sector.
Codexis (NASDAQ:CDXS ) and Sanara MedTech (NASDAQ:SMTI ) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, profitability, risk, media sentiment, community ranking, valuation, earnings, institutional ownership and dividends.
Sanara MedTech has a net margin of -7.19% compared to Codexis' net margin of -87.73%. Sanara MedTech's return on equity of -11.33% beat Codexis' return on equity.
Codexis has a beta of 2.04, meaning that its stock price is 104% more volatile than the S&P 500. Comparatively, Sanara MedTech has a beta of 1.67, meaning that its stock price is 67% more volatile than the S&P 500.
Sanara MedTech has lower revenue, but higher earnings than Codexis. Sanara MedTech is trading at a lower price-to-earnings ratio than Codexis, indicating that it is currently the more affordable of the two stocks.
Codexis received 326 more outperform votes than Sanara MedTech when rated by MarketBeat users. Likewise, 61.21% of users gave Codexis an outperform vote while only 54.55% of users gave Sanara MedTech an outperform vote.
Codexis presently has a consensus price target of $6.80, indicating a potential upside of 88.37%. Sanara MedTech has a consensus price target of $44.00, indicating a potential upside of 44.22%. Given Codexis' higher probable upside, equities research analysts plainly believe Codexis is more favorable than Sanara MedTech.
78.5% of Codexis shares are held by institutional investors. Comparatively, 8.1% of Sanara MedTech shares are held by institutional investors. 6.3% of Codexis shares are held by insiders. Comparatively, 54.1% of Sanara MedTech shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
In the previous week, Sanara MedTech had 11 more articles in the media than Codexis. MarketBeat recorded 14 mentions for Sanara MedTech and 3 mentions for Codexis. Codexis' average media sentiment score of 0.26 beat Sanara MedTech's score of -0.23 indicating that Codexis is being referred to more favorably in the media.
Summary Codexis and Sanara MedTech tied by winning 9 of the 18 factors compared between the two stocks.
This chart shows the number of new MarketBeat users adding CDXS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Related Companies and Tools
